Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
IKT Inhibikase Therapeutics
0.559
-0.015-2.61%
Post Mkt Price
0.560
+0.001+0.23%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
0.94% 4.51M 76.53% 4.64M 76.77% 4.64M 423.90% 14.77M
Selling and administrative expenses
-6.46% 1.54M 3.44% 1.66M 4.31% 1.67M 148.08% 6.51M
Research and development costs
-5.48% 2.98M 25.17% 2.98M 24.06% 3.02M 1,170.87% 11.36M
Other operating expenses
97.78% -7.29K 99.52% -6.55K 96.73% -46.03K -343.92% -3.1M
Operating profit
-0.94% -4.51M -76.53% -4.64M -76.77% -4.64M -423.90% -14.77M
Net non-operating interest income expense
11,906.37% 18.54K 0 99.96% -5 32.24% -19.92K
Non-operating interest income
-- 18.54K -- -- -- -- -- --
Non-operating interest expense
-- 0 -- 0 -99.96% 5 -32.24% 19.92K
Other net income (expense)
Income before tax
-0.52% -4.49M -76.01% -4.64M -75.98% -4.64M -419.19% -14.79M
Income tax
Net income
-0.52% -4.49M -76.01% -4.64M -75.98% -4.64M -419.19% -14.79M
Net income continuous Operations
-0.52% -4.49M -76.01% -4.64M -75.98% -4.64M -419.19% -14.79M
Minority interest income
Net income attributable to the parent company
-0.52% -4.49M -76.01% -4.64M -75.98% -4.64M -419.19% -14.79M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-0.52% -4.49M -76.01% -4.64M -75.98% -4.64M -419.19% -14.79M
Basic earnings per share
0.00% -0.18 18.18% -0.18 30.77% -0.18 -131.43% -0.81
Diluted earnings per share
0.00% -0.18 18.18% -0.18 30.77% -0.18 -131.43% -0.81
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP? Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
CEO: Dr. Milton H. Werner, PhD
Market: NASDAQ
Listing Date: 12/23/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist